Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plant sterol-Stanford University refers to a specific plant sterol (phytosterol) nutraceutical supplement in a gummy format that was evaluated in a Phase 4 clinical trial (NCT04030247) led by Stanford University's South Asian Translational Heart Initiative (SSATHI). The supplement, manufactured by Piper Biosciences, contains 1400 mg of plant sterols per daily dose, administered twice daily. It is designed to lower LDL-cholesterol levels in South Asian patients with low-to-moderate cardiovascular disease risk who do not meet the standard criteria for statin therapy. The mechanism of action involves the competitive inhibition of cholesterol absorption in the intestinal lumen; plant sterols displace dietary and biliary cholesterol from mixed micelles, thereby reducing the amount of cholesterol transported into the bloodstream via the Niemann-Pick C1-Like 1 (NPC1L1) transporter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on plant sterol-Stanford University.